PBS listings to support patients with mesothelioma

From July 1, thousands of Australians and their families suffering from rare cancers and genetic disorders are set to benefit from expanded listings on the Pharmaceutical Benefits Scheme (PBS).   We are expanding the listing for Opdivo® and Yervoy® (nivolumab and ipilimumab), for the treatment of patients with unresectable malignant mesothelioma.   Unresectable malignant mesothelioma…

Details

PBS Listings to Support Patients With Mesothelioma

From July 1, thousands of Australians and their families suffering from rare cancers and genetic disorders are set to benefit from expanded listings on the Pharmaceutical Benefits Scheme (PBS).   We are expanding the listing for Opdivo® and Yervoy® (nivolumab and ipilimumab), for the treatment of patients with unresectable malignant mesothelioma.   Unresectable malignant mesothelioma…

Details

Updated ATAGI Advice Regarding AstraZeneca Vaccine

The Australian Government has today received updated advice from the expert vaccine body, the Australian Technical Advisory Group on Immunisation (ATAGI) about the AstraZeneca COVID-19 vaccine.   The experts at ATAGI have today updated their advice to recommend the Pfizer vaccine be preferred for adults aged 59 and under.   The Government fully accepts the…

Details